🔗 Share this article

Given that the US continues making unprecedented changes to its immunization guidelines, a particular individual has emerged unexpectedly: Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on coronavirus vaccinations throughout the pandemic and has focused upon alleged deaths following COVID-19 vaccination in her recent tenure at the US Food and Drug Administration (FDA).

Scheduled Shifts to Pediatric Immunization Schedule

Health officials planned to unveil major revisions to the pediatric immunization program in December, synchronizing the US with Denmark’s national calendar, according to reports – a significant shift that would put the US out of alignment with many the global community with insufficient data for public health gain. The announcement has been postponed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is set to speak at the event. She was recently named interim head of the FDA’s drug evaluation center, the fifth appointee to run the center this year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a tighter collaboration between the drug and biologics centers as Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon dismantling long-standing vaccines at the FDA.

Dr. Høeg has often pushed for halting specific childhood vaccine recommendations in the US so as to align more in line with the Danish model, a nation with comprehensive healthcare and a population about the size of Wisconsin’s.

So far statements, she has persisted in emphasizing on immunizations – traditionally the domain of Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Questions Over Qualifications

Dr. Høeg has no obvious background in pharmaceutical research, regulation or administrative roles, which has been customary for former leaders of the CBER. She has been employed at the FDA as a senior adviser to the commissioner and CBER since spring.

“She appears not to have the necessary background” for overseeing the CDER, remarked a neurologist and psychiatrist. “She has not conducted a scientific study. She has no expertise in running a major agency. She has no expertise in industry regulation.”

Past directors of CBER would “grasp regulatory frameworks and the research of medication creation”, said a former acting FDA commissioner. “Frankly, she doesn’t have the sort of resume that prior appointees who led CBER have had.”

This division has an vast range of responsibilities at the FDA, the former commissioner emphasized.

“Many people just focuses on the new drug program, but the generic drug division approves thousands of off-brand pharmaceuticals. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one have to be supervised,” she said. “The area you don’t keep your eye on, that is the part that I always told people is going to bite you.”

There is also, a major administrative aspect to the role, which oversees over 5,000 staff members. “It is a massive leadership role, if you do it right,” she added.

Response and Controversial Programs

Regarding inquiries about Dr. Høeg's qualifications and whether this assignment represents increased cooperation among FDA leaders on immunizations, a press secretary said that the “concerns rely on incorrect assumptions”.

“Her experience aligns with the responsibilities of her position,” the official stated, noting the period Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including predictive safety algorithms and shot safety tracking”.

In her interim role, Høeg inherits the commissioner’s new expedited review system, a contentious one-day therapy clearance system that allegedly troubled her predecessors. “By what process are these drugs being picked for this expedited pathway? Who is making the decisions?” Dr. Howard said. “There’s a lot of secrecy going on at the agency right now.”

Overall, he stated, “the Food and Drug Administration looks to be trending towards less stringent regulations of most medications, with the exception of vaccines.”

Established Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if problematic, track record, some experts said. She authored a research paper using non-validated crowd-sourced reports to assess the incidence of myocarditis after COVID-19 immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccinations are riskier than they are.

Included in her “desired changes” for the incoming administration encompassed changing guidelines for recently developed shots and halting “unnecessary” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has reportedly floated the idea of barring young men from receiving COVID-19 vaccinations.

“She is an all-around dogmatist who begins with her preconceived notions and works backwards to fit the data in a extremely disingenuous, dishonest manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of fellow dissenters, {like|